Shuɗin methylene don gano ƙullin limfa na farko: rini, abubuwan bin sawu, da daidaito

Likitan tiyata da ke kula da ciwon daji na nono a matakin farko yana fuskantar takamaiman tambaya: shin ciwon ya kai ƙullayen limfa da ke ƙarƙashin hannu? Cire duk ƙullayen yana ba da amsa, amma yana iya jawo kumburin da taruwar limfa ke haifarwa da matsalolin hannu na dogon lokaci ga marasa lafiya da yawa waɗanda daga baya ake gano cewa ƙullayensu ba su da ciwon. Ra'ayin ƙullin limfa na farko yana ba da damar yin tiyata mai ƙarancin cire nama. Ana gano ƙullin farko (ko ƙaramin rukuni na ƙullaye) da ke karɓar ruwan limfa daga yankin ciwon yayin tiyata, a cire shi, sannan a bincika shi. Idan ba shi da ciwon daji, akwai yiwuwar sauran ƙullayen yankin ma ba su da shi, don haka ana iya kauce wa cire su duka.

Saboda haka, komai ya dogara da gano wannan ƙulli cikin aminci. Wannan shi ne aikin abubuwan bin sawu, kuma a nan ne shuɗin methylene ya shigo.

Abubuwan bin sawu biyu, siginonin zahiri biyu

Wata fahimta marar daidai da ta zama ruwan dare tana ɗaukar shuɗin rini da abin bin sawu mai fitar da radiation kamar nau'ikan abu ɗaya. Abubuwa ne daban da ke samar da siginoni daban.

Ana allurar shuɗin rini (shuɗin methylene, shuɗin isosulfan, ko shuɗin patent) kusa da ciwon ko da'irar da ke kewaye da kan nono. Yana tafiya ta hanyoyin limfa, yana ba hanyar da ƙullin launin shuɗi da ake iya gani. Likitan tiyata yana bin launin da idonsa kai tsaye.

Ana yin allurar abin bin sawu mai fitar da radiation (yawanci sulfur colloid na technetium-99m) dabam. Yana bin hanyar fitar ruwan limfa ɗaya, kuma yana fitar da photons na gamma waɗanda na'urar bincike ta hannu ke ganowa. Yana gano ƙullayen da suke zurfi, waɗanda rininsu bai fito sosai ba, ko waɗanda ba a iya gani.

Haɗa su ana kiransa dabarar amfani da abubuwan bin sawu biyu, kuma har yanzu ita ce hanyar kwatantawa da aka saba amfani da ita a aikin likitanci na zamani. Kowace hanya tana cike gibin gazawar ɗayar: na'urar bincike tana jin abin da ido ba ya iya gani, yayin da rini ke nuna abin da na'urar ke iya tantance wurinsa kusan-kusan kawai. Sauran wannan labarin yana kwatanta shuɗin methylene da sauran zaɓuɓɓuka a cikin wannan tsarin.

Shuɗin methylene kaɗai: yawan ganowa, amma sakamakon rashin cuta na ƙarya na tayar da hankali

Mafi ƙarfafa haɗaɗɗen kimanta amfani da shuɗin methylene shi kaɗai ya fito ne daga bita mai tsari da nazarin haɗa sakamakon bincike 18 a cikin marasa lafiya 1,559 masu ciwon daji na nono waɗanda binciken asibiti bai nuna cuta a ƙullayen hamatarsu ba. An cire binciken da ya yi amfani da wasu shuɗayen rini ko dabarun haɗa radioisotope, don haka wannan kimantawa ce da ta keɓanta ga aikin shuɗin methylene shi kaɗai.

Haɗaɗɗiyar ƙimar ganowa ta kasance 91% (95% CI 88 zuwa 94%). A sauƙaƙe: a kusan 9 cikin 10 na hanyoyin da aka gwada, an gano aƙalla ƙullin limfa na farko guda ɗaya. Sakamakon binciken daban-daban ya kasance daga 75 zuwa 100%, tare da babban bambanci a tsakaninsu (I² kusan 68%). Wannan ya nuna bambance-bambancen ƙarfinsu (mafi yawa 1%), adadin ruwan (0.1 zuwa 10 mL, yawanci 2 ko 5 mL), wuraren allura (kewaye da ciwon ko ƙarƙashin da'irar kan nono), hanyoyin binciken nama, da ƙwarewar likitan tiyata.

Haɗaɗɗiyar ƙimar sakamakon rashin cuta na ƙarya ta kasance 13% (95% CI 9 zuwa 18%). Ƙimar sakamakon rashin cuta na ƙarya tana amsa wata tambaya dabam da ƙimar ganowa: a cikin marasa lafiya da suke da cuta a ƙullayensu da gaske, wane kaso ne gwajin ƙullin farko ya nuna ba su da cuta bisa kuskure? Dabara na iya samun sakamako mai kyau a ma'auni na farko amma mara kyau a na biyu, kuma hakan ne ya faru a nan. Ƙarfin gano masu cuta ya kasance 87%, ƙimar hasashen rashin cuta 91%, da daidaiton sakamako gaba ɗaya 94%.

Marubutan sun ɗauki ƙimar ganowa ta 91% a matsayin abin karɓa, amma sun ga ƙimar sakamakon rashin cuta na ƙarya ta 13% ta yi yawa idan aka kwatanta da ma'aunin tiyata da suka ambata. Sun kuma yi kira da a yi taka-tsantsan wajen dogaro da shuɗin methylene shi kaɗai. Kwatanta ƙananan rukunai bai gano muhimmin bambanci a ƙididdiga tsakanin adadin 2 mL da 5 mL ko tsakanin allura kewaye da ciwon da allura ƙarƙashin da'irar kan nono ba. Amma iyakokin amincewa sun yi faɗi yadda ba za a iya kore yiwuwar bambance-bambance na gaske ba. Shaidar ba ta nuna wani ƙarfi, adadin ruwa, ko wurin allura da ya fi dacewa ba. Don ƙarin bayani kan yadda ake fahimtar kalmomin adadin magani a takardun binciken asibiti, duba yadda ake karanta tsarin binciken asibiti na shuɗin methylene.

Shuɗin methylene kaɗai idan aka kwatanta da shuɗin methylene tare da abin bin sawu mai fitar da radiation

Wani gwajin rabon marasa lafiya ta hanyar bazuwar zaɓi a cibiya ɗaya, a cikin marasa lafiya 60 masu ciwon daji na nono a matakin farko a Hyderabad, ya ware marasa lafiya 30 zuwa 5 mL na shuɗin methylene kaɗai, da wasu 30 zuwa rinin ɗaya tare da 1 mCi na sulfur colloid na technetium-99m da aka tace. Daga nan aka yi wa kowane mara lafiya tiyatar cire sauran ƙullayen hamata a matsayin ma'aunin kwatantawa. Duk rukunin biyu sun gano aƙalla ƙullin farko guda ɗaya a cikin duk marasa lafiya 30 (ƙimar ganowa 100% a kowanne), tare da matsakaicin adadin ƙullayen da aka samu wanda kusan iri ɗaya ne (ƙullaye 3.16 idan aka kwatanta da 3.20).

Wannan cikakkiyar ƙimar ganowa tana da jan hankali har sai an yi la'akari da girman samfurin. Marasa lafiya 7 ne kawai a kowane rukuni suka nuna cuta a ƙullin farko, don haka kowace kimantawar tantance cuta ta dogara da ƙananan abubuwan da suka faru, kuma ba a bayar da iyakokin amincewa ba. Alƙaluman da takardar ta kira na "sakamakon rashin cuta na ƙarya" (8.6% idan aka kwatanta da 4.3%) kuma suna amfani da maƙasudin rabawa da ba na al'ada ba: suna raba sakamakon rashin cuta na ƙarya da duk sakamakon gwajin da ya nuna rashin cuta, maimakon duk marasa lafiyar da suke da cuta a ƙullayensu da gaske. Wannan ya sa sun fi kusa da ɗaya a rage ƙimar hasashen rashin cuta fiye da ƙimar sakamakon rashin cuta na ƙarya da aka saba amfani da ita. Lissafin ƙarfin gano masu cuta da ƙarfin tantance marasa cuta ya bayyana yana nufin hasashen ƙarin cuta a ƙullayen da ba na farko ba, maimakon gano ko akwai bazuwar ciwon daji a hamata. Saboda haka bai kamata a haɗa waɗannan alƙaluma da kimantawar da ta bi tsarin da aka saba ba, kamar 13% da ke sama.

Fassarar wannan gwaji da za a iya karewa tana da iyaka: a cibiya ɗaya mai ƙwarewa, duk dabarun biyu sun gano aƙalla ƙulli guda ɗaya a kowane mara lafiya. Tsarin gwajin bai tabbatar da ikirarinsa na cewa daidaiton tantance cuta ya yi kama ba, kuma rashin samun muhimmin bambanci a ƙididdiga a cikin marasa lafiya 60 bai tabbatar da daidaituwar hanyoyin ba. Amfanin gwajin a aikace yana cikin yanayin inda aka gudanar da shi. A inda babu aikin likitancin nukiliya, shuɗin methylene shi kaɗai ya gano ƙulli a kowane yanayi a nan. Wannan ne ya sa marubutan suka gabatar da shi a matsayin madadin da za a iya amfani da shi, ba a matsayin hanyar da aka tabbatar tana daidai da ɗayar ba.

Bayani kan madogara ta uku

Takardar jagorar wannan labarin ta jera wata bita mai tsari ta 2025 da ta kwatanta shuɗin methylene a wuraren ciwon daji daban-daban. Tun daga lokacin, an janye wannan takarda a Fabrairu 2026 saboda madogarori marasa inganci, inda marubucin da ke kula da tuntuɓa ya danganta kurakuran da kayan aikin da AI ke taimakawa. Ba a haɗa alƙalumanta da aka tara cikin wannan bita ba. Ambatonta yana da muhimmanci saboda dalili ɗaya: tsofaffin kwafin alƙalumanta har yanzu suna yawo a intanet, kuma bai kamata a nakalto su ba.

Shuɗin isosulfan idan aka kwatanta da shuɗin methylene

Game da kwatanta rinin shuɗin methylene da shuɗin isosulfan wajen gano hanyoyin limfa, daidaita fa'ida da haɗarin da wallafe-wallafen bincike ke goyon baya yana da tsayayyen salo: idan batun rashin lafiyar jiki ga rini ne, shuɗin methylene ya fi; idan batun raunin nama a wurin amfani ne, babu wanda ya fi, kuma allurar shuɗin methylene kusa da saman fata tana da ɗan ƙarin rashin fa'ida.

Wata bita mai tsari da ta ƙunshi hanyoyin gano ƙullin farko 61,951 ta gano faruwar matsananciyar rashin lafiyar jiki ga rini sau 94 (haɗaɗɗiyar ƙimar gaba ɗaya bayan yin nauyin ƙididdiga kusan 0.061%). Shuɗin isosulfan ne ya fi samun kimantacciyar ƙima, kusan 0.16%. An danganta ƙaramin adadin rini da yin allura cikin fata da ƙananan ƙimomi. Tsofaffin jerin bayanan asibiti suna nuna irin wannan, inda wani jerin bayanai daga cibiyar kula da nono ya ba da rahoton rashin lafiyar jiki ga rini a cikin 3 daga marasa lafiya 351 da suka karɓi shuɗin isosulfan. Saboda haka ana yawan bayyana shuɗin methylene a matsayin wanda ba ya jawo matsananciyar rashin lafiyar jiki sosai, ko da yake haɗarinsa ba sifili ba ne.

Matsalar da aka fi dangantawa da shuɗin methylene tana faruwa ne a wurin amfani: kumburi, gyambo, da mutuwar nama a fata ko kitse, musamman bayan allura kusa da saman fata ko cikin fata. A cikin nazarin haɗa sakamakon bincike 18 na shuɗin methylene, marasa lafiya biyu a wani bincike sun samu mutuwar fatar wurin allura; wani mara lafiya a wani bincike ya samu mutuwar fata da naman ƙarƙashin fata bayan allura ƙarƙashin da'irar kan nono; sannan marasa lafiya uku a bincike na uku sun samu alamun rashin lafiyar fata ga rini. Ba a samu rashin lafiyar jiki ga shuɗin methylene da ke barazana ga rayuwa a cikin waɗannan bayanai ba. Gwajin rabon marasa lafiya ta bazuwar zaɓi mai marasa lafiya 60 bai ba da rahoton wata illa ta shuɗin methylene ko kaɗan ba, amma kasancewar marasa lafiya 30 ne kawai suka karɓe shi a kowane rukuni, wannan lura ba ta da ƙarfi sosai.

Yaya tsawon lokacin tabon shuɗi yake ɗauka

Marasa lafiya sukan tambayi wannan, kuma amsar gaskiya tana bambanta rinukan, domin yawancin bayanan tabon rini na dogon lokaci sun shafi shuɗin patent, ba rinin da mara lafiyar ya karɓa ba.

An san cewa shuɗin methylene na iya barin tabon da ke kama da zanen fata na ɗan lokaci, kuma wani babban jerin bayanan amfani da shuɗin methylene ya bayyana shi a matsayin matsala ɗaya tilo mai muhimmanci. Game da shuɗin isosulfan, rahotannin da aka wallafa sun bayyana tabon fata da ke ɗaukar daga sa'o'i zuwa makonni. Alƙaluman tabon da ke daɗewa waɗanda suke yawo (tabon da ake iya gani a cikin 36.5% na marasa lafiya a watanni 12, 23.6% a watanni 24, da 8.6% bayan watanni 36) sun fito ne daga wani jerin binciken da ya bi mahalarta zuwa gaba kuma ya yi amfani da shuɗin patent. Wannan rini yana da alaƙa da shuɗin methylene amma ba ɗaya suke ba, don haka bai kamata a nakalto waɗannan a matsayin alƙaluman shuɗin methylene ba. Wani rukunin bincike da ya kwatanta su kai tsaye ya gano sauyin launin fata a cikin 14.1% da shuɗin methylene idan aka kwatanta da 23.7% da shuɗin patent. Shaidar dogon lokaci da ke kwatanta shuɗin methylene musamman da shuɗin isosulfan kai tsaye tana da iyaka. Saboda haka, duk wani labari da ya ayyana yawan watannin da tabon shuɗin methylene yake ɗauka ba tare da ambaton rinin da binciken ba yana yin zato ne. Fitsari mai shuɗi ko kore bayan jiki ya sha rinin yana wucewa bayan ɗan lokaci, kuma an rubuta faruwarsa da shuɗayen rini gaba ɗaya. Amma babu wani daga binciken ƙullin farko da aka bita da ya auna yawan faruwarsa, don haka babu ƙimar faruwa da ya dace a saka a nan. Masu karatu da ke nazarin aminci gaba ɗaya na iya kuma son duba bayyani kan illolin shuɗin methylene da yadda yake hulɗa da wasu magunguna.

Kwatanta abubuwan bin sawu da ma'aunan sakamako

Karanta shaidar kamar mai neman tabbaci

Bambance-bambance uku ne suka ƙunshi jigon wannan batu. Na farko, ƙimar ganowa tana auna ko dabarar tana aiki wajen gano ƙulli; ƙimar sakamakon rashin cuta na ƙarya tana auna ko za a iya amincewa da sakamakon da ya nuna rashin cuta. Shuɗin methylene shi kaɗai yana wuce gwajin farko cikin sauƙi fiye da na biyu. Na biyu, shuɗin rini da abin bin sawu mai fitar da radiation hanyoyin ganowa ne masu zaman kansu, don haka "rini ko abin bin sawu" ba shi ne kwatantawar da ta dace ba. Zaɓin na ainihi shi ne rini kaɗai (wanda ake buƙata a inda babu aikin likitancin nukiliya) ko rini tare da abin bin sawu (hanyar kwatantawa a inda yake samuwa). Na uku, kwatanta aminci dole ya ambaci takamaiman rinin: shuɗin isosulfan yana da rashin fa'ida wajen rashin lafiyar jiki gaba ɗaya ga rini, shuɗin methylene yana da matsalar mutuwar nama a wurin amfani bayan allura kusa da saman fata, kuma alƙaluman tabon da ya fi daɗewa na shuɗin patent ne.

Ga mara lafiya ko mai kula da shi, tambayoyin da za a yi wa likitan tiyata takamaimai ne: wane rini za a yi amfani da shi, shin za a haɗa shi da abin bin sawu mai fitar da radiation, ƙullayen farko nawa ake cirewa yawanci, kuma menene ƙwarewar wannan ƙungiyar wajen ganowa da sakamakon rashin cuta na ƙarya. Don bayanin abin da rinin yake yi a jiki gaba ɗaya da yadda ake nazarinsa, duba ilimin magunguna da rarrabuwar shuɗin methylene a jiki da yadda ake tantance binciken asibiti na shuɗin methylene. Kuma kamar yadda lamarin janye takardar ya nuna, duba kwanan wata da matsayin duk wata bita da aka nuna maka: a fannin shaida da ke sauyawa da sauri, ko haɗaɗɗen alƙalumi mai shekara ɗaya yana iya zama an riga an janye shi.